Novartis says EU approves expanded use of Glivec

Swiss pharmaceutical group Novartis said Monday the European Union will allow it to expand its use of the drug Glivec to treat certain rare forms of gastrointestinal cancer.

The European Commission approved an update to the Glivec label to include 36 months of treatment after surgery "for adults with KIT (CD117)-positive (GIST)," Novartis said in a statement.

"Gastrointestinal stromal tumors are a rare, life-threatening cancer of the ," it said.

They are often difficult to diagnose and treat because they may not cause physical symptoms.

The cancers are usually diagnosed in patients aged between 55 and 65, and are characterised by tumors of connective tissue supporting the digestive tract.

Last year Novartis said sales of Glivec reached $4.7 billion (3.5 billion euros).

add to favorites email to friend print save as pdf

Related Stories

'Rare' cancers in the spotlight at major European conference

Feb 24, 2010

More should be done across Europe to ensure that people with rare forms of cancer are not denied access to the best possible treatment, say the organizers of a major European cancer conference to be held in Milan on 9 and ...

Drug shows promise as new treatment for gut tumor

Jan 11, 2010

A drug that is already an approved therapy for some cancers also might be an effective secondary treatment for a rare tumor of the gastrointestinal tract, according to a team led by researchers from the University of Pittsburgh ...

Recommended for you

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

Expression of privilege in vaccine refusal

Aug 27, 2014

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

User comments